Gleevec

Gleevec is a brand name of imatinib, approved by the FDA in the following formulation(s):

GLEEVEC (imatinib mesylate - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: April 18, 2003
  
  Strength(s): EQ 100MG BASE, EQ 400MG BASE ^[RLD]

Has a generic version of Gleevec been approved?

No. There is currently no therapeutically equivalent version of Gleevec available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gleevec. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyrimidine derivatives and processes for the preparation thereof
  Patent 5,521,184
  Issued: May 28, 1996
  Inventor(s): Zimmermann; Jurg
  Assignee(s): Ciba-Geigy Corporation
  There are described N-phenyl-2-pyrimidine-amine derivatives of formula I ##STR1## wherein R.sub.1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen, R.sup.2, R.sup.3, R.sup.9, X, Y, n and R.sup.10 are defined in claim 1 These compounds can be used, for example, in the therapy of tumoral diseases.
  
  Patent expiration dates:
  
  
  • January 4, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • January 4, 2015
    
    ✓ 
    Patent use: A METHOD FOR TREATING A TUMOR DISEASE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • January 4, 2015
    
  
  
  
  • July 4, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
  Patent 6,894,051
  Issued: May 17, 2005
  Inventor(s): Zimmermann; Jürg & Sutter; Bertrand & Bürger; Hans Michael
  Assignee(s): Novartis AG
  The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.
  
  Patent expiration dates:
  
  
  • May 23, 2019
    
    ✓ 
    Patent use: A METHOD FOR TREATING A TUMOR DISEASE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 23, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Treatment of gastrointestinal stromal tumors
  Patent 6,958,335
  Issued: October 25, 2005
  Inventor(s): Buchdunger; Elisabeth & Capdeville; Renaud & Demetri; George Daniel & Dimitrijevic; Sasa & Druker; Brian Jay & Fletcher; Jonathan A. & Heinrich; Michael C. & Joensuu; Heikki & Silberman; Sandra Leta & Tuveson; David
  Assignee(s): Novartis AG
  Dana-Farber Cancer Institute, Inc.
  Oregon Health & Science University
  4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
  
  Patent expiration dates:
  
  
  • December 19, 2021
    
    ✓ 
    Patent use: GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
  
  
  
  • June 19, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
  Patent 7,544,799
  Issued: June 9, 2009
  Inventor(s): Zimmermann; Jürg & Sutter; Bertrand & Bürger; Hans M
  Assignee(s): Novartis AG
  The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumour therapy.
  
  Patent expiration dates:
  
  
  • January 16, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • July 16, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 19, 2011 - ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
  
  
  • October 19, 2013 - ORPHAN DRUG EXCLUSIVITY
  
  
  • December 19, 2015 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Gleevec Consumer Information (Drugs.com)
• Gleevec Consumer Information (Wolters Kluwer)
• Gleevec Consumer Information (Cerner Multum)
• Gleevec Advanced Consumer Information (Micromedex)
• Gleevec AHFS DI Monographs (ASHP)
• Imatinib Consumer Information (Wolters Kluwer)
• Imatinib Consumer Information (Cerner Multum)
• Imatinib Advanced Consumer Information (Micromedex)
• Imatinib Mesylate AHFS DI Monographs (ASHP)